Log in

NYSE:NVS - Novartis Stock Price, Forecast & News

$92.99
-0.07 (-0.08 %)
(As of 12/15/2019 03:54 PM ET)
Today's Range
$92.65
Now: $92.99
$93.25
50-Day Range
$87.08
MA: $90.00
$93.09
52-Week Range
$72.19
Now: $92.99
$95.00
Volume1.37 million shs
Average Volume1.61 million shs
Market Capitalization$213.11 billion
P/E Ratio18.27
Dividend Yield1.98%
Beta0.6
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone011-41-61-324-1111

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$51.90 billion
Cash Flow$8.14 per share
Book Value$34.07 per share

Profitability

Net Income$12.61 billion

Miscellaneous

Employees125,161
Outstanding Shares2,291,800,000
Market Cap$213.11 billion
Next Earnings Date1/29/2020 (Estimated)
OptionableOptionable

Receive NVS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.


Novartis (NYSE:NVS) Frequently Asked Questions

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

How often does Novartis pay dividends? What is the dividend yield for Novartis?

Novartis announced an annual dividend on Thursday, January 31st. Shareholders of record on Tuesday, March 5th will be given a dividend of $2.8646 per share on Wednesday, March 13th. This represents a yield of 3.27%. The ex-dividend date of this dividend is Monday, March 4th. This is a boost from Novartis's previous annual dividend of $2.33. View Novartis' Dividend History.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) issued its quarterly earnings data on Tuesday, October, 22nd. The company reported $1.41 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.31 by $0.10. The business earned $12.17 billion during the quarter, compared to analyst estimates of $11.67 billion. Novartis had a return on equity of 20.86% and a net margin of 24.43%. Novartis's revenue was up 10.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.32 earnings per share. View Novartis' Earnings History.

When is Novartis' next earnings date?

Novartis is scheduled to release their next quarterly earnings announcement on Wednesday, January 29th 2020. View Earnings Estimates for Novartis.

What price target have analysts set for NVS?

9 analysts have issued 12 month target prices for Novartis' stock. Their forecasts range from $79.16 to $105.00. On average, they expect Novartis' stock price to reach $91.67 in the next year. This suggests that the stock has a possible downside of 1.4%. View Analyst Price Targets for Novartis.

What is the consensus analysts' recommendation for Novartis?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 3 sell ratings, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis.

Has Novartis been receiving favorable news coverage?

News headlines about NVS stock have trended somewhat negative recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Novartis earned a news impact score of -1.9 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Novartis.

Are investors shorting Novartis?

Novartis saw a increase in short interest during the month of November. As of November 29th, there was short interest totalling 2,900,000 shares, an increase of 10.7% from the November 14th total of 2,620,000 shares. Based on an average trading volume of 1,720,000 shares, the short-interest ratio is currently 1.7 days. Approximately 0.1% of the company's stock are short sold. View Novartis' Current Options Chain.

Who are some of Novartis' key competitors?

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Walt Disney (DIS), AbbVie (ABBV), Pfizer (PFE), AT&T (T), Cisco Systems (CSCO), Intel (INTC), NVIDIA (NVDA), Merck & Co., Inc. (MRK) and Verizon Communications (VZ).

Who are Novartis' key executives?

Novartis' management team includes the folowing people:
  • Dr. Vasant Narasimhan, Chief Exec. Officer (Age 43)
  • Mr. Harry Kirsch, Chief Financial Officer (Age 54)
  • Mr. Steffen Lang, Global Head of Technical Operations (Age 52)
  • Ms. Shannon Thyme Klinger, Group Gen. Counsel (Age 48)
  • Dr. Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer (Age 51)

Who are Novartis' major shareholders?

Novartis' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.36%), State Street Corp (0.12%), Schafer Cullen Capital Management Inc (0.12%), Parametric Portfolio Associates LLC (0.11%), Manning & Napier Group LLC (0.11%) and Boston Partners (0.08%).

Which institutional investors are selling Novartis stock?

NVS stock was sold by a variety of institutional investors in the last quarter, including Boston Partners, Eagle Asset Management Inc., Schafer Cullen Capital Management Inc, Thomasville National Bank, Carillon Tower Advisers Inc., Manning & Napier Group LLC, Stifel Financial Corp and SG Americas Securities LLC.

Which institutional investors are buying Novartis stock?

NVS stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Fisher Asset Management LLC, Voloridge Investment Management LLC, Renaissance Group LLC, First Trust Advisors LP, Voya Investment Management LLC, Envestnet Asset Management Inc. and Parametric Portfolio Associates LLC.

How do I buy shares of Novartis?

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Novartis' stock price today?

One share of NVS stock can currently be purchased for approximately $92.99.

How big of a company is Novartis?

Novartis has a market capitalization of $213.11 billion and generates $51.90 billion in revenue each year. The company earns $12.61 billion in net income (profit) each year or $5.09 on an earnings per share basis. Novartis employs 125,161 workers across the globe.View Additional Information About Novartis.

What is Novartis' official website?

The official website for Novartis is http://www.novartis.com/.

How can I contact Novartis?

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 011-41-61-324-1111 or via email at [email protected]


MarketBeat Community Rating for Novartis (NYSE NVS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  476 (Vote Outperform)
Underperform Votes:  542 (Vote Underperform)
Total Votes:  1,018
MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel